Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.525 EUR | +0.60% | 0.00% | -6.48% |
Feb. 27 | Uniphar ups full-year dividend as profit falls but revenue climbs | AN |
Feb. 27 | Uniphar Seeks M&A | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.34 times its sales.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.48% | 734M | C+ | ||
+16.62% | 70.95B | C+ | ||
+2.99% | 25.25B | C+ | ||
+5.38% | 8.67B | C | ||
+6.46% | 8.16B | B | ||
-21.01% | 7.91B | B- | ||
+0.61% | 4.51B | B- | ||
+17.12% | 4.31B | B+ | ||
-0.14% | 4.07B | B- | ||
-3.51% | 3.84B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UPR Stock
- Ratings Uniphar plc